[ad_1]
Johnson & Johnson quietly closed the only factory of the company that produced the series of vaccines against COVID-19 last year, reports “New York Times” today, citing sources familiar with the decision.
The closure is said to be temporary and the factory in Leiden is expected to resume production of the vaccine within a few months, according to the American newspaper. The New York Times writes that it is not clear whether the suspension of production so far has affected the supply of vaccines to countries due to previous stocks.
Johnson & Johnson did not immediately respond to a request for comment. The plant in the Dutch city of Leiden is producing an experimental, potentially more lucrative, vaccine against another virus instead of the COVID-19 vaccine.
The company estimated last month that it would earn up to $ 3.5 billion from sales of the COVID-19 vaccine in 2022, 46 percent more than a year earlier. Johnson & Johnson reported revenue of $ 2.39 billion from sales of the COVID-19 vaccine in 2021, slightly less than the target ($ 2.5 billion).
Because the plant in Leiden is temporarily unavailable, there could be hundreds of millions of doses of Johnson & Johnson vaccine on the market, according to the New York Times. Other factories have been hired to produce the vaccine, but they are not yet technically ready or have not received regulatory approval for the production of the vaccine, writes the American newspaper.
top channel
[ad_2]
Source link